R&D

Osteoporosis
Osteoporosis is a systemic skeletal disease characterized by a reduction of bone density and altred bone quality, with increased fracture risk.

Osteoporosis is a systemic skeletal disease characterized by a reduction of bone  density and altred bone quality, with increased fracture risk. 

A systemic skeletal disease characterized by:

  • Reduction of bone density.
  • Altered bone quality.
  • Increased fracture risk .

The Number: 

In developed countries, the lifetime risk for osteoporotic fractures at the wrist, hip or spine is 30% to 40%, very close to that for coronary heart disease.

An age-related disease 

Osteoporosis is an age related disease and becomes more common in advanced age.

Meaning of fractures

 Elderly suffering with femoral fractures die within a year (15-25%) or become dependent (50%). A single vertebral fracture doubles the risk of subsequent femoral fracture within a year. Multiple vertebral fractures impair patients’ quality of life and increase mortality.

Socioeconomic burden:

  • Inhospital stay 
  • Rehabiltation costs
  • Loss of indipendence
  • Caregiver burden
  • Increased mortality

The innovative solution

Novaicos aims to reduce the fracture incidence with an innovative pharmacological approach, is developing a new biological drug, biocompatible and modulable, reversible and efficacious.

ICOS-Fc work

ICOS-Fc inhibits bone resorpition and allows bone formation.

 

ICOS-Fc inhibit osteoclast  formation and activity in vitro

ICOS-Fc directly inhibits the bone resorbing cells (osteoclasts) without toxic effect.

 

ICOS-Fc activity in models of bone erosion. 

ICOS-Fc is able to restore bone structure in vivo in different mice models
of osteoporosis.

 

On Target

selective inhibits resorbing osteoclats

On Time

quick wash out (20 days) allows bone remodelling